Filing Details

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

CUSIP No. 58549G100

SCHEDULE 13G

1

Name of Reporting Person or
The Medicines Company

2

Check the Appropriate Box if a Member of a Group

(a)

o

(b)

o

3

SEC Use Only

4

Citizenship or Place of Organization
Delaware

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power
3,313,702

6

Shared Voting Power
0

7

Sole Dispositive Power
3,313,702

8

Shared Dispositive Power
0

11

Aggregate Amount Beneficially Owned by Each Reporting Person
3,313,702

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares   o

13

Percent of Class Represented by Amount in Row (11)
10.6%(1)

14

Type of Reporting Person
CO

CUSIP No. 58549G100

SCHEDULE 13G

Item 1(a).

Name of Issuer:
The name of the issuer is Melinta Therapeutics, Inc., a Delaware corporation (the Issuer).

Item 1(b).

Address of Issuers Principal Executive Offices:
The address of the Issuers principal executive offices is 300 George Street, New Haven, CT, 06511.

Item 2(a).

Name of Person Filing:
This Schedule 13G is being filed by The Medicines Company (Medicines).

Item 2(b).

Address of Principal Business Office, or, if none, Residence:
The principal business address for Medicines is 8 Sylvan Way, Parsippany, NJ 07054.

Item 2(c).

Citizenship:
Medicines is a Delaware corporation.

Item 2(d).

Title of Class of Securities:
This Schedule 13G relates to the Issuers common stock, $0.001 par value per share (the Common Stock).

Item 2(e).

CUSIP Number:
58549G100

Item 3.

If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

o

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

§ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________

CUSIP No. 58549G100

SCHEDULE 13G

Item 4.

Ownership:

(a)

Amount beneficially owned:   

3,313,702 shares of Common Stock.

(b)

Percent of class:   

10.6%. The ownership percentage of the Issuers Common Stock is based on 31,325,451 shares of Common Stock outstanding as of January 8, 2018, as reported in the Issuers Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2018.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:

3,313,702 shares of Common Stock.

(ii)

Shared power to vote or to direct the vote:

0

(iii)

Sole power to dispose or to direct the disposition of:

3,313,702 shares of Common Stock.

(iv)

Shared power to dispose or to direct the disposition of:

0

Item 5.

Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   o

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7.

Identification and Classification of Subsidiaries Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8.

Identification and Classification of Members of the Group:

Not applicable.

Item 9.

Notice of Dissolution of Group:

Not applicable.

CUSIP No. 58549G100

SCHEDULE 13G

Item 10.

Certification:

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

The Medicines Company

By:

/s/ Stephen M. Rodin

Name:

Stephen M. Rodin

Title:

Executive Vice President and General Counsel